Table 3.
Number (%) of patients on different antihypertensive treatments on trial according to systolic blood pressure (SBP), diastolic BP (DBP), mean arterial pressure (MAP), and pulse pressure reduction above or below the median
| Systolic BP | Diastolic BP | MAP | Pulse pressure | |||||
|---|---|---|---|---|---|---|---|---|
| below | above | below | above | below | above | below | above | |
| ACEi YES | 319 (53.9) | 273 (46.4)* | 323 (54.6) | 269 (45.8)** | 316 (53.3) | 276 (47.0)* | 317 (53.6) | 275 (46.8)* |
| ndCCB YES | 293 (49.5) | 297 (50.5) | 300 (50.7) | 290 (49.3) | 303 (51.1) | 287 (48.9) | 283 (47.8) | 307 (52.2) |
| VeraTran | 158 (26.7) | 135 (23.0) | 157 (26.5) | 136 (23.1) | 160 (27.0) | 133 (22.7) | 153 (25.8) | 140 (23.8) |
| Trandolapril | 161 (27.2) | 138 (23.5) | 166 (28.0) | 133 (22.6)* | 156 (26.3) | 143 (24.4) | 164 (27.7) | 135 (23.0) |
| Verapamil | 135 (22.8) | 162 (27.6) | 143 (24.2) | 154 (26.2) | 143 (24.1) | 154 (26.2) | 130 (22.0) | 67 (28.4)* |
| Placebo | 138 (23.3) | 152 (26.0) | 126 (21.3) | 165 (28.1)** | 134 (22.6) | 157 (26.8) | 145 (24.5) | 146 (24.8) |
| Diuretic | 97 (16.4) | 132 (22.5)* | 95 (16.1) | 134 (22.8)** | 98 (16.5) | 131 (22.3)* | 105 (17.7) | 124 (21.1) |
| Beta-blocker | 44 (7.4) | 59 (10.0) | 47 (7.9) | 56 (9.5) | 45 (7.6) | 58 (9.9) | 51 (8.6) | 52 (8.8) |
| dCCB | 142 (24.0) | 185 (31.5)** | 145 (24.5) | 182 (31.0)* | 137 (23.1) | 190 (32.4)*** | 160 (27.0) | 167 (28.4) |
| Sympatholytic | 265 (44.8) | 292 (49.7) | 250 (42.2) | 307 (52.2)*** | 256 (43.2) | 301 (51.3)** | 276 (46.6) | 281 (47.8) |
| agent | ||||||||
***
p ≤ 0.001
**
p ≤ 0.01
*
p < 0.05 versus below.
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; dCCB, dihydropyridine calcium channel blocker; ndCCB, non-dihydropyridine calcium channel blocker.